Advitech inc. (TSX VENTURE: AVI) today announced, following the analysis by biostatisticians from JSS Medical Research on the data generated by the 2005 clinical study, statistically significant efficacy results and important clinical trends with regard to Dermylex™ in the treatment of mild to moderate psoriasis. When compared to the placebo group, the Dermylex™ treated group showed a reduction in psoriasis area and severity index (PASI), itching sensation and Body Surface Area (BSA).
